Sarilumab
senyawa kimia
Sarilumab, dijual dengan nama merek Kevzara, adalah sebuah medikasi antibodi monoklonal manusia melawan reseptor interleukin-6.[1] Regeneron Pharmaceuticals dan Sanofi mengembangkan obat tersebut untuk pengobatan artritis reumatoid. Obat tersebut kemudian meraih ijin dari FDA di Amerika Serikat pada 22 Mei 2017 dan ijin dari European Medicines Agency pada 23 Juni 2017.[2]
Referensi
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab"
(PDF). ama-assn.org. American Medical Association.
- ^ "Kevzara: Authorisation details". European Medicines Agency. Diakses tanggal 28 September 2017.
Bacaan tambahan
- Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, Stevenson M (June 2018). "Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal" (PDF). PharmacoEconomics. 36 (12): 1427–1437. doi:10.1007/s40273-018-0677-7. PMID 29882210.
- Genovese MC, van Adelsberg J, Fan C, Graham NM, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TW, van der Heijde D (August 2018). "Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes". Rheumatology (Oxford, England). 57 (8): 1423–1431. doi:10.1093/rheumatology/key121. PMC 6055572
. PMID 29746672. - McCarty D, Robinson A (March 2018). "Efficacy and safety of sarilumab in patients with active rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease. 10 (3): 61–67. doi:10.1177/1759720X17752037. PMC 5802641 . PMID 29492111.
- Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG (2017). "Profile of sarilumab and its potential in the treatment of rheumatoid arthritis". Drug Design, Development and Therapy. 11: 1593–1603. doi:10.2147/DDDT.S100302. PMC 5447699 . PMID 28579757.
Pranala luar
- "Sarilumab". Drug Information Portal. U.S. National Library of Medicine.